Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.

Introduction: A prognostic model to predict liver severity in people with metabolic dysfunction-associated steatotic liver disease (MASLD) is very important, but the accuracy of the most commonly used tools is not yet well established. Objective: The meta-analysis aimed to assess the accuracy of different prognostic serological biomarkers in predicting liver fibrosis severity in people with MASLD. Methods: Adults ≥18 years of age with MASLD were included, with the following: liver biopsy and aspartate aminotransferase-to-platelet ratio (APRI), fibrosis index-4 (FIB-4), non-alcoholic fatty liver disease fibrosis score (NFS), body mass index, aspartate aminotransferase/alanine aminotransferase ratio, diabetes score (BARD score), FibroMeter, FibroTest, enhanced liver fibrosis (ELF), Forns score, and Hepascore. Meta-analyses were performed using a random effects model based on the DerSimonian and Laird methods. The study's risk of bias was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2. Results: In total, 138 articles were included, of which 86 studies with 46,514 participants met the criteria for the meta-analysis. The results for the summary area under the receiver operating characteristic (sAUROC) curve, according to the prognostic models, were as follows: APRI: advanced fibrosis (AF): 0.78, any fibrosis (AnF): 0.76, significant fibrosis (SF): 0.76, cirrhosis: 0.72; FIB-4: cirrhosis: 0.83, AF: 0.81, AnF: 0.77, SF: 0.75; NFS: SF: 0.81, AF: 0.81, AnF: 0.71, cirrhosis: 0.69; BARD score: SF: 0.77, AF: 0.73; FibroMeter: SF: 0.88, AF: 0.84; FibroTest: SF: 0.86, AF: 0.78; and ELF: AF: 0.87. Conclusion: The results of this meta-analysis suggest that, when comparing the scores of serological biomarkers with liver biopsies, the following models showed better diagnostic accuracy in predicting liver fibrosis severity in people with MASLD: FIB-4 for any fibrosis, FibroMeter for significant fibrosis, ELF for advanced fibrosis, and FIB-4 for cirrhosis.Clinical trial registration: [https://clinicaltrials.gov/], identifier [CRD 42020180525].

Manejo protocolizado de la toracostomía mínima en pacientes traumatizados, hospital escuela Antonio Lenin Fonseca, junio 2003- marzo 2005 / Manage protocolized of the minimum toracostomía in traumatized patients, hospital school Antonio Lenin Fonseca, June 2003 - March 2005

El traumatismo de tórax constituye una de las causas más comunes de consulta en el Servicio de Cirugía General del HEALF, siendo la toracostomía la principal terapia en pacientes con hemoneumotórax traumático. Las pautas para su manejo aún varían ampliamente en cuanto a utilización de antibióticos, radiografías y criterios de retiro del tubo de tórax. En dicho cewntro, en el período junio 2003 a marzo 2005 se estandarizó un protocolo de manejo de la toracostomía tubo de tórax conectado a succión continua y luego a sello de agua, uso de antibióticos profilácticos, realización de menos radiografías de control y reducción de la estancia hospitalaria, comparándolo con los pacientes tratados de forma convencional (sello de agus únicamente). La diferencia entre grupos fue evaluada con las pruebas de Chi Cuadrado y Mann Withney "U" test. Fueron 25 pacientes en el grupo experimental y 30 pacientes en el grupo de control. En el primer grupo la estancia hospitalaria logró reducirse a dos días o menos y a dos radiografías de control. En ambos se observó igual número de complicaciones; perpo con un importante ahorro ecnómico de aproximadamente 45, 000 córdobas en el grupo experimental